Nautilus Biotechnology Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
3.7%projected annual EPS growth
Analyst Coverage
1analyst covering
FY Revenue (est.)
$700Knext fiscal year
FY EPS (est.)
-$0.52next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Investments Quarterly143.4MTarget: Sufficient to fund operations through 2027
Quarterly Cash Burn Rate Quarterly12.8MTarget: Disciplined capital allocation to preserve runway
Full-Year Revenue AnnuallyTarget: Approximately 500000
Watch Items
- Iterative Mapping Early Access Program (EAP) ExpansionTrigger: Securing additional named biopharma and academic customers beyond Baylor College of MedicineAction: Scale service lab capabilities and validate additional proteoform assays (e.g., oncology-focused assays in H2 2026)
- Nautilus Voyager Platform Commercial LaunchTrigger: Opening the platform for pre-orders in late 2026Action: Place beta units with customers in late Q3/Q4 2026 and prepare for customer installations in early 2027
- Cash Runway and Capital PreservationTrigger: Cash reserves dropping below $100 million without a clear path to commercial revenueAction: Evaluate strategic financing, partnerships, or further operational cost-reduction measures
Research as of 20 Jun 2026